Nanotechnology for pain management: Current and future therapeutic interventions
Source abstract
Abstract
Pain is one of the most common medical conditions and affects more Americans than diabetes, heart disease, and cancer combined. Current pain treatments mainly rely on opioid analgesics and remain unsatisfactory. The life-threatening side effects and addictive properties of opioids demand new therapeutic approaches. Nanomedicine may be able to address these challenges as it allows for sensitive and targeted treatments without some of the burdens associated with current clinical pain therapies. This review discusses the physiology of pain, the current landscape of pain treatment, novel targets for pain treatment, and recent and ongoing efforts to effectively treat pain using nanotechnology-based approaches. We highl ight advances in nanoparticle-based drug delivery to reduce side effects, gene therapy to tackle the source of pain, and nanomaterials-based scavenging to proactively mediate pain signaling.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Pain Mechanisms and Treatments · Pain Management and Opioid Use · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. S.M. Schappert, C.W. Burt, Ambulatory Care Visits to Physician Offices, Hospital Outpatient Departments, and Emergency Departments: United States, 2001–02, Vital and Health Statistics, Series 13, Data from the National Health Survey 13, 2006, pp. 1–66.
2. The global burden of pain: the tip of the iceberg?10.1213/ANE.0000000000001519 ↗
3. Treating chronic pain: new knowledge, more choices10.7812/TPP/05-067 ↗
4. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders10.1016/j.jpain.2008.05.005 ↗
5. Prevalence of chronic pain and high-impact chronic pain among adults – United States, 201610.15585/mmwr.mm6736a2 ↗
6. Incidence and impact of pain conditions and comorbid illnesses10.2147/JPR.S24170 ↗
7. The economic costs of pain in the United States10.1016/j.jpain.2012.03.009 ↗
8. Some orthodontists’ experiences of volunteering for a community orthodontic initiative10.1016/j.ajodo.2018.05.017 ↗
9. Classification of Chronic Pain, Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy, Pain, Suppl. 3, 1986, pp. 1–226.
10. G Protein-coupled receptors: dynamic machines for signaling pain and itch10.1016/j.neuron.2015.11.001 ↗
11. Glial cells and chronic pain10.1177/1073858409360822 ↗
12. TRPV1: a target for next generation analgesics10.2174/157015908784533888 ↗
13. Sodium channels and pain10.1007/978-3-662-46450-2_3 ↗
14. Interleukin-6: an emerging regulator of pathological pain10.1186/s12974-016-0607-6 ↗
15. Visceral versus somatic pain: similarities and differences10.1159/000268115 ↗
16. Neuropathic pain: mechanisms and their clinical implications
17. New concepts of pain10.1016/j.berh.2019.04.007 ↗
18. Acetaminophen from liver to brain: new insights into drug pharmacological action and toxicity10.1016/j.phrs.2016.02.020 ↗
19. Effect of drugs modulating serotonergic system on the analgesic action of paracetamol in mice10.4103/0253-7613.182874 ↗
20. Acetaminophen-induced hepatotoxicity: a comprehensive update
21. Antidepressants in the treatment of neuropathic pain10.1111/j.1742-7843.2005.pto_96696601.x ↗
22. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia10.1002/14651858.CD007115.pub3 ↗
23. Analgesic mechanisms of antidepressants for neuropathic pain10.3390/ijms18112483 ↗
24. Unravelling the mystery of capsaicin: a tool to understand and treat pain10.1124/pr.112.006163 ↗
25. Steroids as pain relief adjuvants
26. Adding dexmedetomidine to lidocaine for intravenous regional anesthesia
27. Dexmedetomidine prolongs spinal anaesthesia induced by levobupivacaine 0.5% in guinea-pigs10.1211/jpp.57.11.0006 ↗
28. Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block10.1111/j.1399-6576.2006.00919.x ↗
29. Dexmedetomidine enhances the local anesthetic action of lidocaine via an alpha-2A adrenoceptor10.1213/ane.0b013e318176be73 ↗
30. Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets10.2174/1871527311312010017 ↗
31. Endogenous and exogenous opioids in pain10.1146/annurev-neuro-080317-061522 ↗
32. Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl10.1016/j.neuropharm.2019.02.008 ↗
33. Opioid therapy and its side effects: a review
34. Novel opioid analgesics and side effects10.1021/acschemneuro.7b00195 ↗
35. The opioid epidemic: crisis and solutions10.1146/annurev-pharmtox-010617-052534 ↗
36. Nerve blocks for chronic pain10.1016/j.nec.2014.07.006 ↗
37. The role of continuous peripheral nerve blocks
38. Deciphering the role of endogenous opioids in high-frequency TENS using low and high doses of naloxone10.1016/j.pain.2010.07.012 ↗
39. Spinal cord stimulation for neuropathic pain: current perspectives10.2147/JPR.S37589 ↗
40. The Na(V)1.7 sodium channel: from molecule to man10.1038/nrn3404 ↗
41. Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy10.1002/ana.22485 ↗
42. Nerve growth factor antagonists: is the future of monoclonal antibodies becoming clearer?10.1007/s40265-017-0781-6 ↗
43. Tanezumab: finally a monoclonal antibody for pain relief
44. Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief10.1126/scitranslmed.aal3447 ↗
45. Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission10.1073/pnas.1706656114 ↗
46. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome10.1073/pnas.1721891115 ↗
47. Emerging structures and ligands for P2X(3) and P2X(4) receptors-towards novel treatments of neuropathic pain10.1007/s11302-010-9182-y ↗
48. Discovery of potent antiallodynic agents for neuropathic pain targeting P2X3 receptors10.1021/acschemneuro.6b00401 ↗
49. Identification of second-generation P2X3 antagonists for treatment of pain10.1016/j.bmcl.2018.02.039 ↗
50. Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways10.1016/j.cell.2014.04.040 ↗
51. Macrophage angiotensin II type 2 receptor triggers neuropathic pain10.1073/pnas.1721815115 ↗
52. In vivo biodistribution of nanoparticles10.2217/nnm.11.79 ↗
53. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
54. M.I. Noordin, Advance Delivery System Dosage Form for Analgesic, their Rationale, and Specialty, 2017.10.5772/68096 ↗
55. Liposome encapsulation prolongs alfentanil spinal analgesia and alters systemic redistribution in the rat10.1097/00000542-199209000-00019 ↗
56. Prolonged analgesia and decreased toxicity with liposomal morphine in a mouse model10.1213/00000539-199410000-00015 ↗
57. Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs10.1097/00000542-199905000-00025 ↗
58. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles10.1023/A:1012098005098 ↗
59. Opioid-based micro and nanoparticulate formulations: alternative approach on pain management10.3109/02652048.2015.1134687 ↗
60. Extended-release epidural morphine (DepoDur): an old drug with a new profile10.1111/j.1533-2500.2005.00048.x ↗
61. Extended-release morphine sulfate in treatment of severe acute and chronic pain
62. Prevention of opioid abuse and treatment of opioid addiction: current status and future possibilities10.1146/annurev-bioeng-060418-052155 ↗
63. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety-reply10.1177/2042098615595360 ↗
64. Mu opioid receptor: a gateway to drug addiction10.1016/j.conb.2004.05.005 ↗
65. Squalene targets pro- and anti-inflammatory mediators and pathways to modulate over-activation of neutrophils, monocytes and macrophages10.1016/j.jff.2015.03.009 ↗
66. A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine10.1126/sciadv.aau5148 ↗
67. Alternative splicing of G protein-coupled receptors: relevance to pain management10.1016/j.mayocp.2015.06.010 ↗
68. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days10.1016/j.nano.2017.07.010 ↗
69. Mesoporous silica particles as a multifunctional delivery system for pain relief in experimental neuropathy10.1002/adhm.201500996 ↗
70. Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain10.1073/pnas.2000500117 ↗
71. Hybrid hydrogel composed of polymeric nanocapsules co-loading lidocaine and prilocaine for topical intraoral anesthesia10.1038/s41598-018-36382-4 ↗
72. Time to analgesia onset and pharmacokinetics after separate and combined administration of liposome bupivacaine and bupivacaine HCl: considerations for clinicians10.2174/1874325001610010094 ↗
73. Continuous peripheral nerve blocks: a review of the published evidence10.1213/ANE.0b013e3182285e01 ↗
74. Benzocaine-loaded polymeric nanocapsules: study of the anesthetic activities10.1002/jps.22829 ↗
75. Development of hydrophilic nanocarriers for the charged form of the local anesthetic articaine10.1016/j.colsurfb.2014.05.035 ↗
76. Characterization of articaine-loaded poly(ε-caprolactone) nanocapsules and solid lipid nanoparticles in hydrogels for topical formulations10.1166/jnn.2018.15235 ↗
77. Preparation and characterization of poly(ε-caprolactone) nanospheres containing the local anesthetic lidocaine10.1002/jps.23350 ↗
78. Emerging roles of liposomal bupivacaine in anesthesia practice10.4103/joacp.JOACP_375_15 ↗
79. Protein-functionalized PLGA nanoparticles of lamotrigine for neuropathic pain management10.1208/s12249-014-0235-3 ↗
80. Effect of lamotrigine on Na(v)1.4 voltage-gated sodium channels10.1254/jphs.13116SC ↗
81. Prolongation of epidural analgesia using solid lipid nanoparticles as drug carrier for lidocaine10.1097/AAP.0b013e31823fc058 ↗
82. Nanotechnology: a promising new paradigm for the control of pain10.1093/pm/pnx131 ↗
83. Local anesthetic systemic toxicity: current perspectives10.2147/LRA.S154512 ↗
84. Advances of nano-structured extended-release local anesthetics10.1186/s11671-019-3241-2 ↗
85. Local anesthetic toxicity: acute and chronic management10.1002/ams2.265 ↗
86. Physiological and pharmacologic aspects of peripheral nerve blocks10.4103/0970-9185.161679 ↗
87. A re-examination of tetrodotoxin for prolonged duration local anesthesia10.1097/00000542-199807000-00019 ↗
88. Site 1 sodium channel blockers prolong the duration of sciatic nerve blockade from tricyclic antidepressants10.1016/j.pain.2004.04.027 ↗
89. Polymer-tetrodotoxin conjugates to induce prolonged duration local anesthesia with minimal toxicity10.1038/s41467-019-10296-9 ↗
90. Hollow silica nanoparticles penetrate the peripheral nerve and enhance the nerve blockade from tetrodotoxin10.1021/acs.nanolett.7b02461 ↗
91. Prolonged regional nerve blockade. Injectable biodegradable bupivacaine/polyester microspheres10.1097/00000542-199606000-00017 ↗
92. Prolonged nerve blockade delays the onset of neuropathic pain10.1073/pnas.1214634109 ↗
93. Crotoxin conjugated to SBA-15 nanostructured mesoporous silica induces long-last analgesic effect in the neuropathic pain model in mice10.3390/toxins11120679 ↗
94. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure10.1016/j.jhep.2016.11.017 ↗
95. Silymarin/silybin and chronic liver disease: a marriage of many years10.3390/molecules22020191 ↗
96. Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity
97. Nanomaterials for the local and targeted delivery of osteoarthritis drugs10.1155/2012/673968 ↗
98. A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain10.1038/s41565-019-0568-x ↗
99. Immunoliposomes: a review on functionalization strategies and targets for drug delivery10.1016/j.colsurfb.2017.07.085 ↗
100. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition10.36076/ppj.2013/16/E199 ↗